ClinicalTrials.gg
RecruitingNCT07424781FLEXUpdated Feb 20, 2026

Fluoxetine on Emotional Experience (FLEX) Study

An interventional study of Fluoxetine and Placebo in Depression - Major Depressive Disorder, Irritability and Depression, sponsored by University of Oxford. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by University of Oxford · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies testing fluoxetine in Depression — 9 open to participants now, 10 under way, 1 of them phase 3. Fluoxetine · Depression.

Planned enrollment
24th of 42
80 · median 97
Started
2025
with 4 others
No phase
10 of 43
3 open now
Registered
41st of 43
by date
Lead sponsor
3 of 43
University of Oxford

Among the 43 studies testing fluoxetine in Depression, this one is the 24th largest by planned enrollment of the 42 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 with no phase, and was the 41st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

9 of the 43 studies testing fluoxetine in Depression are open now, in 7 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About fluoxetine

Fluoxetine: first FDA approval 1987 (SARAFEM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 24 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing fluoxetine in Depression, or all of them as a file.
02

Study summary

The goal of this clinical medicine study is to investigate how does antidepressant fluoxetine modulate anger processing in healthy young people . The main questions it aims is to answer are:

  1. How does fluoxetine affect responses to anger-related stimuli such as words, faces, and autobiographical recall?
  2. How does fluoxetine influence responses during frustration induction in frustrative non-reward and threat paradigms?
  3. Does the effect manifest in physiological markers, including heart rate variability and facial expressions?

Researchers will compare fluoxetine to a placebo to see if drug fluoxetine affects anger processing.

Participants will:

Take 20mg fluoxetine or a placebo every day for 7 days. Visit the university site for questionnaire and tasks assessments. Heart rate variability and facial expressions will be recorded in some of the tasks.

03

Conditions studied

  • Depression - Major Depressive Disorder
  • Irritability
  • Depression

Browse trials for

Keywords

  • depression
  • young people
  • fluoxetine
  • irritability
  • anger
04

Who can participate

Ages eligible
18 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be aged 18-24 years (inclusive)
  • Be resident in the UK for the duration of the study
  • Have normal or corrected to normal vision
  • Participant is willing and able to give for participation in the research
  • Sufficiently fluent English to understand and complete the study

Exclusion criteria

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

Psychiatric History:

  • Current or past diagnosis of any psychiatric disorder, as determined by the Structured Clinical Interview for the (SCID-5) and self-report. This includes, but is not limited to, depression, anxiety disorders, alcohol or drug dependency, personality disorders, suicidal ideation, and other psychiatric conditions;
  • First degree relative with a diagnosis of mania;

Lifestyle:

  • Heavy smoker or vaper (> 10 cigarettes per day, or >2 mL e-liquid, or >15mg/day from a nicotine patch);
  • Heavy use of caffeine (drink > 4 of 250ml cups/cans of coffee or energy drinks per day);
  • Heavy drinker (drink >14 standard alcoholic drinks per week);
  • Current or recent use (in the last 3 months) of any psychoactive substance according to self-report and a urine drug test screening for recent use of 10 common recreational substances;

Physical Health:

  • Severely underweight or overweight in a manner that renders them unsuitable for the study in the opinion of the study medical advisor;
  • Known to fluoxetine, such as to fluoxetine or any component in its formulation;
  • Pregnancy, as determined by a urine pregnancy test or plans to become pregnant within the next 3 months;
  • Breastfeeding;
  • Not able to consume gelatine;

Medical History:

  • Past or ongoing health issue which, in the opinion of the study medical advisor, may interfere with the safety of the participant or the scientific integrity of the study, including but not limited to: seizures or epilepsy, heart rhythm problem, renal disease, hepatic disease, glaucoma, diabetes, bleeding disorders or clotting conditions (e.g., haemophilia, thrombocytopenia);
  • Diagnosis of a significant neurological condition (e.g., epilepsy, multiple sclerosis, traumatic brain injury).
  • Diagnosis of a neurodevelopmental condition, such as autism spectrum disorder (ASD) or attention-deficit/hyperactivity disorder (ADHD);
  • Current or recent use of medication that might interfere or interact with the effects of fluoxetine, in the opinion of the study medical advisor, including but not limited to: monoamine oxidase inhibitors (MAOIs), medications affecting serotonin levels (e.g., tramadol, triptans, St. John's Wort), anticoagulants or blood thinners (e.g., warfarin), anti-inflammatory medications (e.g., aspirin, ibuprofen), or medications known to affect heart rhythm;

Prior Study Participation:

  • Participation in any other psychological or medical experiment involving taking any kind of drug/medication/vaccine, within the last 3 months;
  • Participation in any other study involving the current or similar tasks, within the last 6 months;

Others

•Any other significant finding which may arise during the screening process and which, in the opinion of the Principal Investigator/medical advisor, may influence the scientific integrity of the study, or the participant's ability to participate in the study.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    fluoxetine

    Participants will be taking 20mg fluoxetine daily.

    Drug: Fluoxetine

  • Placebo comparator
    placebo

    Participants will be taking one placebo capsule daily.

    Drug: Placebo

Interventions

  • Participants will receive 20mg of fluoxetine daily for 7 days. Tablets encapsulated to aid blinding.

  • DrugPlacebo

    Participants will receive one dose placebo (sucrose) daily for 7 days. Tablets encapsulated to aid blinding.

06

What researchers measure

Primary outcomes

  1. Behavioral Measure: Facial Expression Recognition Task (FERT)

    Recognition of angry faces in the Facial Expression Recognition Task

    Time frame: On the last day of the 7-day treatment

Secondary outcomes

  1. Behavioural Measure: The Affordances Task

    Performance on an affordances task in which participants have to decide to fight or escape under threatening situations with different environmental affordance conditions.

    Time frame: On the last day of the 7-day treatment

  2. Behavioural Measure: Emotional Categorization Task (ECAT)

    Performance on recognising and memorising anger related words in the Emotional Categorization Task (ECAT)

    Time frame: On the last day of the 7-day treatment.

  3. Performance on Carnival Task

    Performance on an anger induction task in which the study's rigged design creates frustrating non-reward responses.

    Time frame: On the last day of the 7-day treatment.

  4. Subjective Measure: Rest Task

    Participants' rating of anger-related emotions during a resting task.

    Time frame: On the last day of the 7-day treatment.

  5. Subjective Measure: Anger Memory Recall Task

    Participants' ratings of anger-related emotions and bodily sensations during a task that involves guided imagery of a past personal experience.

    Time frame: On the last day of the 7-day treatment.

  6. Physiological Measure: Heart Rate Variability

    Heart rate variability measures across a battery of anger-induction tasks.

    Time frame: On the last day of the 7-day treatment.

  7. Physiological Measure: Facial Expression

    Video recordings that identify facial expressions across a battery of anger-induction tasks.

    Time frame: On the last day of the 7-day treatment.

  8. Behavioural measure: Emotional Recognition Memory Task (EMEM)

    Description: Performance on recognising and memorising anger related words in the Emotional Recognition Memory Task (EMEM).

    Time frame: On the last day of the 7-day treatment.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data which has been fully de-identified and relevant supporting materials (e.g., study protocol, data dictionary, and analysis documentation) may be shared with other academic organisations in the future, including those outside of the UK and the EU. Participants will be informed of this and specific consent to this is obtained within the Informed Consent Form.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: Data will be available in a few months after all data has been completed (ETA Oct 2026), unblinding has occurred (ETA Dec 2026), and all data analyses has been completed (Dec 2027).

Access criteria: Fully de-identified individual participant data (IPD) and relevant supporting documentation may be shared with academic researchers for scientific research purposes. Access will be limited to researchers affiliated with recognised academic or research institutions, including those outside of the UK and EU. Approved researchers will be granted access only to fully de-identified IPD and relevant supporting materials. Data will be shared via secure transfer methods or through a controlled-access data repository.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 14 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 14 months is below that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Feb 20, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07424781
Collaborators
Wellcome Trust, National Institute for Health Research, United Kingdom
Responsible party
Catherine Harmer (Professor of Cognitive Neuroscience, University of Oxford) — Principal investigator
First posted
Feb 20, 2026
Start date
Oct 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 20, 2026

Study contacts

Catherine Harmer, PhD
Contact
catherine.harmer@psych.ox.ac.uk
+441865 618326
Ye Wo, MSc
Contact
ye.wo@psych.ox.ac.uk
+447564300004

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluoxetine

Start the discussion